Management of radiation maculopathy

Arun D. Singh, Sheila Pabon, Mary E. Aronow

Research output: Contribution to journalArticlepeer-review

Abstract

Radiation maculopathy is a delayed onset complication of radiation exposure. Various host and radiation parameters determine the risk of developing radiation maculopathy, which may be progressive. Total radiation dose delivered to the macula is the most important modifiable factor. Radiation maculopathy is not a singular entity as clinical manifestations reflect combined effects of all damaged tissues. Current treatment using anti-vascular endothelial growth factor agents offers only a short-term, temporary, and modest visual improvement. Avoidance or prevention of radiation maculopathy may be the best option. Use of periocular steroid during plaque brachytherapy may prevent radiation maculopathy over the short term. Newer designs and techniques of delivering radiation to the eye need to be explored.

Original languageEnglish (US)
Pages (from-to)26-31
Number of pages6
JournalOphthalmic Research
Volume48
Issue numberSUPPL. 1
DOIs
StatePublished - Aug 2012
Externally publishedYes

Keywords

  • Aflibercept
  • Bevacizumab
  • Maculopathy
  • Radiation
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'Management of radiation maculopathy'. Together they form a unique fingerprint.

Cite this